Renalytix Plc (LON:RENX – Get Free Report)’s stock price was up 11.5% during trading on Friday . The company traded as high as GBX 2.90 and last traded at GBX 2.90. Approximately 3,599,768 shares changed hands during mid-day trading, an increase of 292% from the average daily volume of 917,177 shares. The stock had previously closed at GBX 2.60.
Renalytix Price Performance
The firm has a market cap of £12.67 million, a P/E ratio of -0.72 and a beta of 1.79. The company has a quick ratio of 2.42, a current ratio of 1.57 and a debt-to-equity ratio of -483.33. The business’s 50 day moving average is GBX 2.01 and its two-hundred day moving average is GBX 3.17.
Renalytix Company Profile
Renalytix (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s lead product is KidneyIntelX, which has been granted Breakthrough Designation by the U.S. Food and Drug Administration and which is being designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com).
Featured Articles
- Five stocks we like better than Renalytix
- AST SpaceMobile Stock Sinks as SpaceX Fallout Rattles Space Sector
- Aehr Test Systems Stock Soars on Earnings, Eyes Over 150% Revenue Growth
- TSMC Just Gave AI Chip Bulls Another Reason to Stay Confident
- GE Aerospace Faces a Prove-It Moment in Q2 Earnings
Receive News & Ratings for Renalytix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Renalytix and related companies with MarketBeat.com's FREE daily email newsletter.
